{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:34:44Z","timestamp":1791408884192,"version":"4.3.3"},"reference-count":59,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:00:00Z","timestamp":1696291200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"F Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.clml.2023.09.009","type":"journal-article","created":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T07:13:39Z","timestamp":1696922019000},"page":"e1-e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Overall Survival in Patients With Multiple Myeloma in the U.S.: A Systematic Literature Review of Racial Disparities"],"prefix":"10.1016","volume":"24","author":[{"given":"Joseph","family":"Mikhael","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allie","family":"Cichewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth S.","family":"Mearns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allicia","family":"Girvan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8528-9901","authenticated-orcid":false,"given":"Vicki","family":"Pierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neda Al","family":"Rawashdh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archibong","family":"Yellow-Duke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Frank","family":"Cornell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Nixon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.clml.2023.09.009_bib0001","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.amjmed.2022.08.030","article-title":"Multiple myeloma for the primary care provider: a practical review to promote earlier diagnosis among diverse populations","volume":"136","author":"Mikhael","year":"2023","journal-title":"Am J Med"},{"key":"10.1016\/j.clml.2023.09.009_bib0002","unstructured":"National Organization for Rare Disorders. Multiple myeloma. 2022; Available at: https:\/\/rarediseases.org\/rare-diseases\/multiple-myeloma\/. Accessed: September 29, 2022."},{"issue":"1","key":"10.1016\/j.clml.2023.09.009_bib0003","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1182\/asheducation-2017.1.498","article-title":"Management of multiple myeloma in the newly diagnosed patient","volume":"2017","author":"Mateos","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2023.09.009_bib0004","unstructured":"National Institutes of Health Surveillance, Epidemiology, and End Results Program. Cancer Statistics Facts: Myeloma. 2022; Available at: https:\/\/seer.cancer.gov\/statfacts\/html. Accessed: September 29, 2022."},{"key":"#cr-split#-10.1016\/j.clml.2023.09.009_bib0005.1","unstructured":"American Cancer Society. Cancer facts & figures for African American\/Black people 2022-2024. 2022"},{"key":"#cr-split#-10.1016\/j.clml.2023.09.009_bib0005.2","unstructured":"Available at: https:\/\/www.cancer.org\/content\/dam\/cancer-org\/research\/cancer-facts-and-statistics\/cancer-facts-and-figures-for-african-americans\/2022-2024-cff-aa.pdf. Accessed: September 29, 2022."},{"issue":"2","key":"10.1016\/j.clml.2023.09.009_bib0006","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41408-020-0284-7","article-title":"Dissecting racial disparities in multiple myeloma","volume":"10","author":"Marinac","year":"2020","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.clml.2023.09.009_bib0007","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/bloodadvances.2021005482","article-title":"Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials","volume":"6","author":"Kanapuru","year":"2022","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.clml.2023.09.009_bib0008","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2019.1870","article-title":"Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018","volume":"5","author":"Loree","year":"2019","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.clml.2023.09.009_bib0009","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41408-018-0102-7","article-title":"Disease and outcome disparities in multiple myeloma: exploring the role of race\/ethnicity in the Cooperative Group clinical trials","volume":"8","author":"Ailawadhi","year":"2018","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.clml.2023.09.009_bib0010","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/s41416-020-01038-6","article-title":"Cancer health disparities in racial\/ethnic minorities in the United States","volume":"124","author":"Zavala","year":"2021","journal-title":"British J Cancer"},{"issue":"1","key":"10.1016\/j.clml.2023.09.009_bib0011","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s13045-020-00980-5","article-title":"Emerging agents and regimens for multiple myeloma","volume":"13","author":"Yang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.clml.2023.09.009_bib0012","unstructured":"Cancer.Net. Multiple myeloma: statistics. 2022; Available at: https:\/\/www.cancer.net\/cancer-types\/multiple-myeloma\/statistics. Accessed: September 29, 2022."},{"issue":"10","key":"10.1016\/j.clml.2023.09.009_bib0013","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41408-018-0132-1","article-title":"Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry","volume":"8","author":"Baughn","year":"2018","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1016\/j.clml.2023.09.009_bib0014","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-019-0177-9","article-title":"Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients","volume":"9","author":"Kazandjian","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.clml.2023.09.009_bib0015","unstructured":"International Myeloma Foundation. What are some disparities in the treatment and care of multiple myeloma patients? 2022; Available at: https:\/\/www.myeloma.org\/diversity\/are-some-disparities-treatment-care-multiple-myeloma-patients. Accessed: September 29, 2022."},{"key":"10.1016\/j.clml.2023.09.009_bib0016","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1200\/EDBK_238551","article-title":"Many shades of disparities in myeloma care","volume":"39","author":"Ganguly","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.clml.2023.09.009_sbref0017","volume":"6","author":"Higgins","year":"2022"},{"key":"10.1016\/j.clml.2023.09.009_bib0018","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"6 suppl 2","key":"10.1016\/j.clml.2023.09.009_bib0019","doi-asserted-by":"crossref","first-page":"PR04","DOI":"10.1158\/1538-7755.DISP19-PR04","article-title":"Understanding outcome disparities in multiple myeloma: a multiethnic comparison of clinical characteristics in Hispanics","volume":"29","author":"Belachew","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.clml.2023.09.009_bib0020","doi-asserted-by":"crossref","unstructured":"Cirstea D, Fillmore N, Yameen H, et\u00a0al. Abstract 1569: racial differences in incidence and impact of TP53 deletion on outcome in African American and Caucasian veterans with multiple myeloma. Cancer Res. 2-19;79(13).","DOI":"10.1158\/1538-7445.AM2019-1569"},{"issue":"suppl 15","key":"10.1016\/j.clml.2023.09.009_bib0021","doi-asserted-by":"crossref","first-page":"e20019","DOI":"10.1200\/JCO.2021.39.15_suppl.e20019","article-title":"Race as a predictor of outcome in young patients with myeloma","volume":"39","author":"Cottini","year":"2021","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.09.009_bib0022","first-page":"2177","article-title":"Similar survival for African American and Caucasian multiple myeloma patients receiving auto-SCT","volume":"130","author":"Dell","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.09.009_bib0023","first-page":"3285","article-title":"Transplant still relevant even in the era of novel treatments for multiple myeloma: National cancer database analysis","volume":"130","author":"Devarakonda","year":"2017","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.09.009_bib0024","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1182\/blood-2018-99-118392","article-title":"Disparities in healthcare resource utilization for multiple myeloma","volume":"132","author":"Fiala","year":"2018","journal-title":"Blood"},{"issue":"15","key":"10.1016\/j.clml.2023.09.009_bib0025","doi-asserted-by":"crossref","first-page":"8033","DOI":"10.1200\/JCO.2018.36.15_suppl.8033","article-title":"Lack of racial disparity in outcome of African American (AA) and Caucasian patients with symptomatic multiple myeloma (MM) at the Veterans Affairs (VA) hospitals","volume":"36","author":"Fillmore","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.clml.2023.09.009_bib0026","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1200\/jco.2016.34.7_suppl.311","article-title":"Disparity in early mortality among racial groups with multiple myeloma in the United States: a national cancer data base study of 108,352 patients","volume":"34","author":"Gonsalves","year":"2016","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2023.09.009_bib0027","first-page":"S139","article-title":"Outcomes of autologous stem cell transplant (ASCT) in African-American (AA) patients with multiple myeloma (MM)","volume":"21","author":"Jain","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"suppl 15","key":"10.1016\/j.clml.2023.09.009_bib0028","doi-asserted-by":"crossref","first-page":"e18170","DOI":"10.1200\/JCO.2019.37.15_suppl.e18170","article-title":"Comparable survival of African-Americans and Caucasian patients with multiple myeloma: a hospital-based study including 117,926 patients","volume":"37","author":"Malek","year":"2019","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.09.009_bib0029","doi-asserted-by":"crossref","first-page":"S307","DOI":"10.1016\/S2152-2650(20)30954-X","article-title":"MM-345: differential toxicities and survival outcomes by race: chimeric antigen receptor (CAR) T-cell therapy for myeloma","volume":"20","author":"Nooka","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"23","key":"10.1016\/j.clml.2023.09.009_bib0030","doi-asserted-by":"crossref","first-page":"4508","DOI":"10.1182\/blood.V126.23.4508.4508","article-title":"Racial disparities in incidence and survival for patients with multiple myeloma in the United States","volume":"126","author":"Radhakrishnan","year":"2015","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.09.009_bib0031","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2020-134837","article-title":"African-Americans multiple-myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: a propensity-score matched analysis","volume":"136","author":"Saini","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2023.09.009_bib0032","doi-asserted-by":"crossref","first-page":"S231","DOI":"10.1016\/j.bbmt.2015.11.639","article-title":"Outcome of patients with multiple myeloma by ethnicity in the setting of autologous stem cell transplant","volume":"22","author":"Sasaki","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"suppl 15","key":"10.1016\/j.clml.2023.09.009_bib0033","doi-asserted-by":"crossref","first-page":"e19529","DOI":"10.1200\/jco.2015.33.15_suppl.e19529","article-title":"Characteristics and survival of African American (AA) newly diagnosed multiple myeloma (NDMM) patients (Pts): a report from the connect MM Registry","volume":"33","author":"Toomey","year":"2015","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.clml.2023.09.009_bib0034","doi-asserted-by":"crossref","first-page":"6570","DOI":"10.1200\/JCO.2019.37.15_suppl.6570","article-title":"Impact of race\/ethnicity in the clinical presentation and outcomes of patients with multiple myeloma in an underserved urban population","volume":"37","author":"Torres","year":"2019","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.clml.2023.09.009_bib0035","doi-asserted-by":"crossref","first-page":"e17604","DOI":"10.1200\/jco.2015.33.15_suppl.e17604","article-title":"Age-related racial\/ethnic differences in the impact of targeted therapy and immunomodulatory agents on survival of patients with multiple myeloma: a population-based analysis","volume":"33","author":"Tun","year":"2015","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2023.09.009_bib0036","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1002\/cam4.1246","article-title":"Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis","volume":"6","author":"Ailawadhi","year":"2017","journal-title":"Cancer Med"},{"issue":"8","key":"10.1016\/j.clml.2023.09.009_bib0037","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1002\/cncr.31237","article-title":"Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: a comprehensive look at racial disparities","volume":"124","author":"Ailawadhi","year":"2018","journal-title":"Cancer"},{"issue":"19","key":"10.1016\/j.clml.2023.09.009_bib0038","doi-asserted-by":"crossref","first-page":"4332","DOI":"10.1002\/cncr.33089","article-title":"Association between race and treatment patterns and survival outcomes in multiple myeloma: a connect MM registry analysis","volume":"126","author":"Ailawadhi","year":"2020","journal-title":"Cancer"},{"issue":"20","key":"10.1016\/j.clml.2023.09.009_bib0039","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1182\/bloodadvances.2019000308","article-title":"Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis","volume":"3","author":"Ailawadhi","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.clml.2023.09.009_bib0040","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/cncr.33208","article-title":"African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States","volume":"127","author":"Badar","year":"2020","journal-title":"Cancer"},{"issue":"20","key":"10.1016\/j.clml.2023.09.009_bib0041","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1002\/cncr.30183","article-title":"Impact of marital status, insurance status, income, and race\/ethnicity on the survival of younger patients diagnosed with multiple myeloma in the United States","volume":"122","author":"Costa","year":"2016","journal-title":"Cancer"},{"issue":"9","key":"10.1016\/j.clml.2023.09.009_bib0042","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/cncr.30526","article-title":"Racial disparities in treatment use for multiple myeloma","volume":"123","author":"Fiala","year":"2017","journal-title":"Cancer"},{"issue":"18","key":"10.1016\/j.clml.2023.09.009_bib0043","doi-asserted-by":"crossref","first-page":"3511","DOI":"10.1182\/bloodadvances.2020004001","article-title":"Lack of differential impact of del17p on survival in African Americans compared with White patients with multiple myeloma: a VA study","volume":"5","author":"Fillmore","year":"2021","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.clml.2023.09.009_bib0044","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.hemonc.2020.09.005","article-title":"Disparities in the enrollment to systemic therapy and survival for patients with multiple myeloma","volume":"14","author":"Jayakrishnan","year":"2021","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.clml.2023.09.009_bib0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2021.106542","article-title":"Association of insurance disparities and survival in adults with multiple myeloma: a non-concurrent cohort study","volume":"104","author":"Makhani","year":"2021","journal-title":"Leuk Res"},{"issue":"16","key":"10.1016\/j.clml.2023.09.009_bib0046","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1002\/cncr.30747","article-title":"Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: a CIBMTR report","volume":"123","author":"Schriber","year":"2017","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.clml.2023.09.009_bib0047","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1016\/j.bbmt.2016.07.007","article-title":"Post-transplant outcomes in high-risk compared with non-high-risk multiple myeloma: a CIBMTR analysis","volume":"22","author":"Scott","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.clml.2023.09.009_bib0048","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/cncr.29160","article-title":"Disparities in Black and White patients with multiple myeloma referred for autologous hematopoietic transplantation: a single center study","volume":"121","author":"Bhatnagar","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2023.09.009_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2021.101974","article-title":"Multiple myeloma, race, insurance and treatment","volume":"73","author":"Joshi","year":"2021","journal-title":"Cancer Epidemiol"},{"issue":"4","key":"10.1016\/j.clml.2023.09.009_bib0050","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1016\/j.clml.2020.11.013","article-title":"Multiple myeloma in Hispanics: incidence, characteristics, survival, results of discovery, and validation using real-world and connect MM registry data","volume":"21","author":"Kaur","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"10.1016\/j.clml.2023.09.009_bib0051","doi-asserted-by":"crossref","first-page":"e680","DOI":"10.1016\/j.clml.2021.04.006","article-title":"Disparities in utilization of autologous stem cell transplantation as consolidative therapy for multiple myeloma: a single institution retrospective review","volume":"21","author":"Lupak","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2023.09.009_bib0052","unstructured":"Cancer.Net. Multiple myeloma: risk factors. 2021; Available at: https:\/\/www.cancer.net\/cancer-types\/multiple-myeloma\/risk-factors. Accessed: October 19, 2022."},{"issue":"4","key":"10.1016\/j.clml.2023.09.009_bib0053","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1200\/JOP.19.00309","article-title":"Timeliness of initial therapy in multiple myeloma: trends and factors affecting patient care","volume":"16","author":"Kumar","year":"2020","journal-title":"JCO Oncol Pract"},{"issue":"suppl 1","key":"10.1016\/j.clml.2023.09.009_bib0054","doi-asserted-by":"crossref","first-page":"4729","DOI":"10.1182\/blood-2019-129147","article-title":"Impact of socioeconomic factors on timeliness of first line chemotherapy and survival in patients with active multiple myeloma","volume":"134","author":"Jayakrishnan","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.09.009_bib0055","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jclinepi.2022.08.012","article-title":"Understanding variation in the results of real-world evidence studies that seem to address the same question","volume":"151","author":"Wang","year":"2022","journal-title":"J Clin Epidemiol"},{"issue":"24","key":"10.1016\/j.clml.2023.09.009_bib0056","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1182\/blood.2019000406","article-title":"With equal access, African American patients have superior survival compared to white patients with multiple myeloma: a VA study","volume":"133","author":"Fillmore","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.09.009_bib0057","unstructured":"National Cancer Institute, Surveillance, Epidemiology, and End Results Program. Number of Persons by Race and Hispanic Ethnicity for SEER Participants (2020 Census Data). Available at: https:\/\/seer.cancer.gov\/registries\/data.html. Accessed: October 19, 2022."},{"issue":"2","key":"10.1016\/j.clml.2023.09.009_bib0058","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/s41408-022-00633-5","article-title":"Black patients with multiple myeloma have better survival than white patients when treated equally: a matched cohort study","volume":"12","author":"Dong","year":"2022","journal-title":"Blood Cancer J"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023021328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265023021328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:43:42Z","timestamp":1761871422000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265023021328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":59,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S2152265023021328"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.09.009","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overall Survival in Patients With Multiple Myeloma in the U.S.: A Systematic Literature Review of Racial Disparities","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.09.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}